OC
ARKG icon

Oppenheimer & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History

Oppenheimer & Co’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$599K Buy
14,251
+480
+3% +$15.3K 0.01% 1173
2026
Q1 		$364K Buy
13,771
+1,345
+11% +$39.4K ﹤0.01% 1314
2025
Q4 		$360K Buy
+12,426
New +$373K 0.01% 1208
2025
Q3 		– Sell
-19,816
Closed -$483K – 1656
2025
Q2 		$483K Buy
19,816
+1,153
+6% +$25.3K 0.01% 1158
2025
Q1 		$387K Buy
+18,663
New +$469K 0.01% 1170
2022
Q3 		– Sell
-7,801
Closed -$245K – 1370
2022
Q2 		$245K Sell
7,801
-7,199
-48% -$252K 0.01% 1180
2022
Q1 		$689K Buy
15,000
+664
+5% +$31.7K 0.01% 886
2021
Q4 		$877K Sell
14,336
-4,093
-22% -$283K 0.02% 827
2021
Q3 		$1.38M Sell
18,429
-122
-0.7% -$10.2K 0.03% 629
2021
Q2 		$1.72M Buy
18,551
+3,645
+24% +$310K 0.03% 566
2021
Q1 		$1.32M Buy
14,906
+9,901
+198% +$982K 0.03% 603
2020
Q4 		$467K Buy
5,005
+470
+10% +$37.4K 0.01% 920
2020
Q3 		$289K Buy
+4,535
New +$266K 0.01% 997

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co's ARKG Position: Q2 2026 in Review

Oppenheimer & Co increased its ARK Genomic Revolution ETF (ARKG) stake by 3.5% in Q2 2026, buying an estimated $15.3K and bringing the position to 14,251 shares worth $599K. The position accounts for 0.01% of the portfolio, ranked #1173.

Oppenheimer & Co first reported a position in ARKG in Q3 2020 and has held it in 13 quarters since. The position peaked at $1.72M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Oppenheimer & Co held 14,251 shares of ARK Genomic Revolution ETF worth $599K as of Q2 2026.
  • Oppenheimer & Co bought 480 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $15.3K.
  • ARK Genomic Revolution ETF made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1173 holding.
  • Oppenheimer & Co first reported a position in ARK Genomic Revolution ETF in Q3 2020 and has held it in 13 quarters since.
  • Oppenheimer & Co's ARK Genomic Revolution ETF position peaked at $1.72M in Q2 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.